Top Markets
Coin of the day
Poniard Pharmaceuticals, Inc. Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals, Inc.

PARD
Classifica tra le azioni #42764
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the... Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Prezzo delle azioni
$0.0001
Ultima sincronizzazione: 2026-08-11
Capitalizzazione di mercato
$150.00
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Poniard Pharmaceuticals, Inc. (PARD)

Categoria

Rapporto P/B per Poniard Pharmaceuticals, Inc. (PARD)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Poniard Pharmaceuticals, Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Poniard Pharmaceuticals, Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
6.2613 -
US
6.3483 -
NL
- -
CH
3.634 -
BE
- -
KR